Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar Carcinoma.
Saved in:
| Title: | Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar Carcinoma. |
|---|---|
| Authors: | Abou-Alfa GK; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Medical College at Cornell University, New York, NY, USA.; Department of Medicine, Medical School, Trinity College Dublin University, Dublin, Ireland., Meyer T; Department of Oncology, Royal Free Hospital, London, UK.; Department of Oncology, UCL Cancer Institute, University College London, London, UK., Do RKG; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Medical College at Cornell University, New York, NY, USA., Piha-Paul SA; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Light JS; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Sherrin S; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Yaqubie A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., O'Neill AC; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Harding JJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Medical College at Cornell University, New York, NY, USA., Al-Rajabi R; Department of Medicine, University of Kansas Medical Center, Kansas City, KS, USA., Denlinger CS; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Cano P; Department of Hematology/Oncology, Sudbury Regional Hospital, Sudbury, ON, Canada., Cornelius AS; Department of Medicine, Helen DeVos Children's Hospital, Grand Rapids, MI, USA., O'Reilly EM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Medical College at Cornell University, New York, NY, USA., DiPrimeo D; Biometrics, Puma Biotechnology Inc., Los Angeles, CA, USA., Eli LD; Translational Medicine and Biometrics, Puma Biotechnology Inc., Los Angeles, CA, USA., Gordan JD; Division of Hematology/Oncology, CSF GI Medical Oncology, San Francisco, CA, USA., Solit DB; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Medical College at Cornell University, New York, NY, USA. |
| Source: | Liver cancer [Liver Cancer] 2024 Aug 08; Vol. 14 (1), pp. 58-67. Date of Electronic Publication: 2024 Aug 08 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: S. Karger Country of Publication: Switzerland NLM ID: 101597993 Publication Model: eCollection Cited Medium: Print ISSN: 2235-1795 (Print) Linking ISSN: 16645553 NLM ISO Abbreviation: Liver Cancer Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2235-1795 |
|---|---|
| DOI: | 10.1159/000540290 |
